Serratia infection laboratory findings: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) |
YazanDaaboul (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Serratia infection}} | {{Serratia infection}} | ||
{{CMG}} | |||
==Overview== | ==Overview== | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
| Line 76: | Line 76: | ||
| Trimethoprim/Sulfamethoxazole (TMP - SMX)||2||S | | Trimethoprim/Sulfamethoxazole (TMP - SMX)||2||S | ||
|} | |} | ||
<sup> | |||
* Reflects MIC of first component<br> | <sup><nowiki>* Reflects MIC of first component</nowiki><br> | ||
** Screen for metallo-beta-lactamase production<ref name="pmid23731823">{{cite journal| author=Rasheed JK, Kitchel B, Zhu W, Anderson KF, Clark NC, Ferraro MJ et al.| title=New Delhi metallo-β-lactamase-producing Enterobacteriaceae, United States. | journal=Emerg Infect Dis | year= 2013 | volume= 19 | issue= 6 | pages= 870-8 | pmid=23731823 | doi=10.3201/eid1906.121515 | pmc=PMC3713825 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23731823 }} </ref><br> | <nowiki>** Screen for metallo-beta-lactamase production</nowiki><ref name="pmid23731823">{{cite journal| author=Rasheed JK, Kitchel B, Zhu W, Anderson KF, Clark NC, Ferraro MJ et al.| title=New Delhi metallo-β-lactamase-producing Enterobacteriaceae, United States. | journal=Emerg Infect Dis | year= 2013 | volume= 19 | issue= 6 | pages= 870-8 | pmid=23731823 | doi=10.3201/eid1906.121515 | pmc=PMC3713825 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23731823 }} </ref><br> | ||
*** Based on FDA break points<br> | <nowiki>*** Based on FDA break points</nowiki><br> | ||
Abbreviations: I=Intermediate; R=Resistant; S=Susceptible<br></sup> | Abbreviations: I=Intermediate; R=Resistant; S=Susceptible<br></sup> | ||
<sup>Table adapted from Antimicrobial Resistance Bank - Serratia marcescens. Centers for Disease Control and Prevention.<ref> Antimicrobial Resistance Bank - Serratia marcescens. Centers for Disease Control and Prevention. http://www.cdc.gov/drugresistance/pdf/0122.pdf. Accessed on January 5 2016</ref></sup> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 16:07, 11 January 2016
|
Serratia infection Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Serratia infection laboratory findings On the Web |
|
American Roentgen Ray Society Images of Serratia infection laboratory findings |
|
Risk calculators and risk factors for Serratia infection laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Laboratory Findings
Culture Growth
According to the Centers for Disease Control and Prevention (CDC), the following procedure should be followed to properly culture "Serratia:[1]
- Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)
- Growth Conditions:
- Temperature: 35 °C (95 °F)
- Atmosphere: Aerobic
- Procedure
- Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)
- Open vial aseptically to avoid contamination
- Using a sterile loop, remove a small amount of frozen isolate from the top of the vial
- Aseptically transfer the loop to BAP
- Use streak plate method to isolate single colonies
- Incubate inverted phase at 35 °C (95 °F) for 18-24 hours
MIC Results and Interpretation
The following table demonstrates the MIC results following Serratia culture/antibiogram and interpretation:
| MIC (µg/ml) Results and Interpretation | ||
| Drug | MIC | Interpretation |
| Amikacin | 2 | S |
| Amoxicillin/Clavulanic Acid * | > 32 | R |
| Ampicillin | > 32 | R |
| Ampicillin/Sulbactam | > 32 | R |
| Aztreonam | 16 | R |
| Cefazolin | > 32 | R |
| Cefepime | ≤ 0.5 | S |
| Cefotaxime | ≤ 1 | S |
| Cefoxitin | 2 | S |
| Ceftazidime | 1 | S |
| Ceftriaxone | ≤ 1 | S |
| Ciprofloxacin | ≤ 0.12 | S |
| Colistin | > 4 | _ |
| Doripenem | _ | _ |
| Ertapenem | > 16 | R |
| Gentamicin | 0.5 | S |
| Imipenem | > 32 | R |
| Imipenem + chelators ** | _ | _ |
| Levofloxacin | ≤ 0.25 | S |
| Meropenem | > 16 | R |
| Piperacillin/Tazobactam * | 2 | S |
| Polymyxin B | > 4 | _ |
| Tetracycline | 8 | I |
| Tigecycline *** | 1 | S |
| Tobramycin | 1 | S |
| Trimethoprim/Sulfamethoxazole (TMP - SMX) | 2 | S |
* Reflects MIC of first component
** Screen for metallo-beta-lactamase production[2]
*** Based on FDA break points
Abbreviations: I=Intermediate; R=Resistant; S=Susceptible
Table adapted from Antimicrobial Resistance Bank - Serratia marcescens. Centers for Disease Control and Prevention.[3]
References
- ↑ Antimicrobial Resistance Bank - Serratia marcescens. Centers for Disease Control and Prevention. http://www.cdc.gov/drugresistance/pdf/0122.pdf. Accessed on January 5 2016
- ↑ Rasheed JK, Kitchel B, Zhu W, Anderson KF, Clark NC, Ferraro MJ; et al. (2013). "New Delhi metallo-β-lactamase-producing Enterobacteriaceae, United States". Emerg Infect Dis. 19 (6): 870–8. doi:10.3201/eid1906.121515. PMC 3713825. PMID 23731823.
- ↑ Antimicrobial Resistance Bank - Serratia marcescens. Centers for Disease Control and Prevention. http://www.cdc.gov/drugresistance/pdf/0122.pdf. Accessed on January 5 2016